NASDAQ · TVRD
Tvardi Therapeutics, Inc.
$0.86-$0.02 (-2.73%)
Tvardi Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.83% below the high.
Loading market information…
NASDAQ · OSA · USD
Stock price, earnings
Quote as of Jun 17, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ProSomnus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 6.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow ProSomnus, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ProSomnus, Inc. develops and provides specialized oral appliance therapy solutions crafted to alleviate obstructive sleep apnea (OSA). This enterprise, which originated in 2016, maintains its headquarters in Pleasanton, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2022 |
|---|
| Jun 30, 2022 |
| -$0.18 |
| $4.86M |
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.86-$0.02 (-2.73%)
Tvardi Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.83% below the high.
$4.58+$0.22 (+5.05%)
NeuroMetrix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.17% below the high.
$0.33+$0.33 (+100.0%)
Centogene N.V.’s quoted price sits in the lower half of its reported 52-week range, 24.24% below the high.
$0.36$0.00 (0.0%)
Turnstone Biologics Corp.’s quoted price sits in the lower half of its reported 52-week range, 84.3% below the high.
$3.49+$0.05 (+1.45%)
Neoleukin Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.44% below the high.
$0.14$0.00 (0.0%)
Omega Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.79% below the high.
$1.12+$0.16 (+16.15%)
SunLink Health Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.62% below the high.
CA$9.00+CA$0.20 (+2.27%)
COSCIENS Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.27% below the high.
